Literature DB >> 16647558

Earlier administration of Rituximab allows higher rate of long-lasting response in adult patients with autoimmune thrombocytopenia.

Francesco Zaja, Nicola Vianelli, Marta Battista, Alessandra Sperotto, Francesca Patriarca, Valentina Tomadini, Carla Filì, Monica Tani, Michele Baccarani, Renato Fanin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16647558     DOI： 10.1016/j.exphem.2006.02.009

Source DB:  PubMed          Journal:  Exp Hematol        ISSN： 0301-472X            Impact factor:   3.084


× No keyword cloud information.
  12 in total

1.  Rituximab in immune thrombocytopenia: transient responses, low rate of sustained remissions and poor response to further therapy in refractory patients.

Authors:  Aamer Aleem; Ahmed S Alaskar; Farja Algahtani; Mushtaq Rather; Muhamad Hitham Almahayni; Abdulkarim Al-Momen
Journal:  Int J Hematol       Date:  2010-07-17       Impact factor: 2.490

2.  Slow responses to standard dose rituximab in immune thrombocytopenic purpura.

Authors:  Kevin Kelly; Mary Gleeson; Philip Thomas Murphy
Journal:  Haematologica       Date:  2009-03       Impact factor: 9.941

3.  Response to steroids predicts response to rituximab in pediatric chronic immune thrombocytopenia.

Authors:  Rachael F Grace; Carolyn M Bennett; A Kim Ritchey; Michael Jeng; Courtney D Thornburg; Michele P Lambert; Michelle Neier; Michael Recht; Manjusha Kumar; Victor Blanchette; Robert J Klaassen; George R Buchanan; Margaret Heisel Kurth; Diane J Nugent; Alexis A Thompson; Kimo Stine; Leslie A Kalish; Ellis J Neufeld
Journal:  Pediatr Blood Cancer       Date:  2011-06-14       Impact factor: 3.167

4.  Efficacy and safety of rituximab in Japanese patients with relapsed chronic immune thrombocytopenia refractory to conventional therapy.

Authors:  Yoshitaka Miyakawa; Shinya Katsutani; Takahiro Yano; Shosaku Nomura; Kaichi Nishiwaki; Yoshiaki Tomiyama; Masaaki Higashihara; Yukari Shirasugi; Masakatsu Nishikawa; Katsutoshi Ozaki; Takayuki Abe; Kayoko Kikuchi; Yuzuru Kanakura; Kingo Fujimura; Yasuo Ikeda; Shinichiro Okamoto
Journal:  Int J Hematol       Date:  2015-12       Impact factor: 2.490

5.  Clinical Practice Updates in the Management Of Immune Thrombocytopenia.

Authors:  Ayesha M Khan; Halina Mydra; Ana Nevarez
Journal:  P T       Date:  2017-12

6.  Low Dose Rituximab in Chronic ITP: Still an Option in Resource Limited Settings.

Authors:  Rajan Kapoor; Rajiv Kumar; M Mahapatra; H P Pati; Suman Kumar Pramanik
Journal:  Indian J Hematol Blood Transfus       Date:  2016-12-19       Impact factor: 0.900

7.  Rituximab salvage therapy in adults with immune thrombocytopenia: retrospective study on efficacy and safety profiles.

Authors:  Emilie Reboursiere; H Fouques; G Maigne; H Johnson; S Chantepie; A C Gac; O Reman; M Macro; K Benabed; X Troussard; G Damaj; S Cheze
Journal:  Int J Hematol       Date:  2016-04-04       Impact factor: 2.490

Review 8.  The potential utility of B cell-directed biologic therapy in autoimmune diseases.

Authors:  D G Arkfeld
Journal:  Rheumatol Int       Date:  2007-10-24       Impact factor: 2.631

9.  Rituximab Therapy in Adults with Refractory Symptomatic Immune Thrombocytopenia: Long-Term Follow-Up of 15 Cases.

Authors:  Fehmi Hindilerden; İpek Yönal-Hindilerden; Mustafa Nuri Yenerel; Meliha Nalçacı; Reyhan Diz-Küçükkaya
Journal:  Turk J Haematol       Date:  2016-04-22       Impact factor: 1.831

10.  Real-world Experience of Rituximab in Immune Thrombocytopenia.

Authors:  Kundan Mishra; Suman Kumar; Aditya Jandial; Kamal Kant Sahu; Rajeev Sandal; Ankur Ahuja; Sanjeev Khera; Yanamandra Uday; Rajiv Kumar; Rajan Kapoor; Tarun Verma; Sanjeevan Sharma; Jasjit Singh; Satyaranjan Das; Tathagat Chatterjee; Ajay Sharma; Velu Nair
Journal:  Indian J Hematol Blood Transfus       Date:  2021-01-01       Impact factor: 0.915
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.